CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.
Medicare and Medicaid Patients With Opioid Addiction Less Likely …
2 days ago · Patients addicted to opioids receive less mental health care if they are only covered by public insurance, compared with patients receiving care through alternate funding, …
Managed Healthcare Executive - Payer and Population Health …
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
Novo Nordisk Terminates Collaboration with Hims & Hers
Jun 23, 2025 · The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims …
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes …
Apr 23, 2025 · Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected …
Novo Nordisk and WeightWatchers Partnership, Plus $299 …
6 days ago · Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their prescription filled through CenterWell Pharmacy, now …
Alexandra Gerlach - managedhealthcareexecutive.com
Jun 1, 2025 · Alexandra Gerlach is an associate editor at Pharmacy Times.
After Pride: The Fight for LGBTQ+ Health Equity Isn’t Over
5 days ago · As sweeping policy shifts and rising restrictions threaten LGBTQ+ health access, providers, payers and employers reflect on what’s at stake in Pride Month's end—and what it …
Prime Study Finds Low Long-Term Adherence to GLP-1 Obesity …
6 days ago · A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in adherence in 2024, suggesting there is an evolving …
FDA Approves Hereditary Angioedema Therapy, Andembry
Jun 18, 2025 · The FDA has approved CSL Behring’s Andembry (garadacimab-gxii), a new therapy for the prophylactic treatment of hereditary angioedema (HAE) in patients aged 12 …